{"name":"SENTYNL THERAPS INC","slug":"sentynl-theraps-inc","ticker":"","exchange":"","domain":"sentynltheraps.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Zokinvy first approved","drug":"Zokinvy","drugSlug":"lonafarnib","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Nulibry first approved","drug":"Nulibry","drugSlug":"fosdenopterin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Zokinvy","genericName":"LONAFARNIB","slug":"lonafarnib","indication":"Hutchinson-Gilford syndrome","status":"marketed"},{"name":"Nulibry","genericName":"FOSDENOPTERIN","slug":"fosdenopterin","indication":"Molybdenum cofactor deficiency type A","status":"marketed"}]}],"pipeline":[{"name":"Zokinvy","genericName":"LONAFARNIB","slug":"lonafarnib","phase":"marketed","mechanism":"Lonafarnib prevents farnesylation of progerin and similar proteins by inhibiting farnesyltransferase.","indications":["Hutchinson-Gilford syndrome","Processingdeficient progeroid laminopathies"],"catalyst":""},{"name":"Nulibry","genericName":"FOSDENOPTERIN","slug":"fosdenopterin","phase":"marketed","mechanism":"Nulibry works by providing a functional molybdenum cofactor to cells, bypassing the genetic defect that causes molybdenum cofactor deficiency type A.","indications":["Molybdenum cofactor deficiency type A"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}